Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Solstice Oncology has secured $225 million in a Series A financing led by RA Capital Management to advance its neoadjuvant immuno-oncology therapy, porustobart.
PRIVATESep 09, 2026•about 4 hours ago
Amount Raised
$225 Million
Round Type
Series A
BiotechnologyTherapeuticsBiopharma
Investors
ForbionCanaan PartnersRa Capital Management
Description
Solstice Oncology, a clinical-stage company focused on treating cancer earlier, has launched with a $225 million Series A financing. The funding will support the advancement of porustobart, a differentiated CTLA-4 antibody across clinical indications. Harbour BioMed, its partner, discovered and developed porustobart and has licensed it for exclusive development outside Greater China. The collaboration aims to enhance global advancement of this promising therapy.
Company Information
Company
Solstice Oncology
About
Harbour BioMed is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Don't miss Solstice Oncology's next move
Get an email the moment Solstice Oncology raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Solstice Oncology's next move
